Sun Pharmaceutical Industries Limited has released an investor presentation for February 2026. The presentation details the company's business operations, financial performance, R&D, manufacturing capabilities, corporate governance, and history of key deals. It highlights Sun Pharma's position as a leading global specialty generic company operating in over 100 countries, with a diversified revenue base across US Formulations (31%), India Formulations (33%), Emerging Markets (18%), Rest of World (14%), and API & Others (4%). The company showcases an impressive track record of growth in sales, EBITDA, adjusted net profit, and adjusted EPS from FY10 to FY25, with strong profitability and return ratios. Sun Pharma emphasizes its best-in-class profitability compared to the top 9 Indian Pharma companies. The presentation also details its business operations across various geographies, including the US, India, Emerging Markets, and Rest of World, along with its global consumer healthcare and API businesses. Significant focus is placed on Research & Development, with cumulative R&D spend of approximately ₹325 billion to date and R&D spend at 6.2% of sales for FY25. The company's global manufacturing infrastructure comprises 40 facilities approved by major regulatory authorities. Sun Pharma's corporate governance is highlighted, with a balanced board of directors. Key financials for FY21-FY25 and Q3 FY26 are provided, showing consistent revenue growth and improving margins. The presentation also outlines the company's history of strategic acquisitions and in-licensing deals aimed at strengthening its product portfolio and market presence.
